„Luteolin offers novel therapeutic regimen in rotenone-induced Parkinson disease via modulation of TNF-α/FXMRP/serotonin/tyrosine hydroxylase signaling pathway“, NJPS, sv. 40, izd. 2, str. 251–262, pros. 2025, doi: 10.54548/.